Local drug intake as eye drops is preferable for the treatment of the pathological processes within the eye. However, topical drug application is much less effective for the treatment of diseases, which include inner structures of the eye, due to the poor transport of the drug into the eye. And more, when one needs to deliver a protein molecule into the eye compartments, it especially represents a major challenge due to the limited ocular penetration. The work presents two different perspective ways for drug delivery into the eye. One implies biocompatible and nontoxic calcium phosphate (CaP) particles as vehicles for the low molecular weight substance, enalaprilat, an inhibitor of angiotensin-converting enzyme. The second one uses multilayer polyion complex nanoparticles of superoxide dismutase, SOD1, (Nano-SOD1), to treat inflammatory eye diseases. The drawbacks and prospects for both approaches are discussed.